Helicos names Trifunovich as CEO; Sunshine to start trials with lead drug;

 @FierceBiotech:Genzyme sees signs of remission in 5-year MS drug data. Report | Follow @FierceBiotech

  @JohnCFierce: FDA's Top Q4 Blockbuster Drug Decisions | Follow @JohnCFierce

Special Report: Top 10 Medical Device Companies: 2010. Report

> Helicos BioSciences' board of directors has appointed Dr. Ivan Trifunovich as the company's president and CEO. Helicos release

> Sunshine Biopharma, a development stage pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it issued a letter to its shareholders advising that it had filed for patent protection worldwide and expects to enter Phase I clinical trials for its principal drug. News

> The University of Maryland BioPark in Baltimore got a big boost from the private sector with the announcement that the School of Medicine is teaming up with Advanced Particle Therapy to build a $200 million cancer treatment center. Article

> Drug delivery's death is greatly exaggerated. Story 

> Winnipeg biotech company DiaMedica says it has achieved positive results from a Type 1 diabetes study using its main compound in a widely accepted animal model. News

> Antitope Ltd in Cambridge has struck a research collaboration with Chugai Pharmaceuticals Co., Ltd of Tokyo, Japan. News

And Finally... Along with giving curries and other spicy Asian dishes a bright golden color and peppery flavor, turmeric has been used for centuries as an herbal medicine to treat a host of ailments, like upset stomach, arthritic pain, cuts and bruises. Mahtab Jafari, associate professor of pharmaceutical sciences at UC Irvine, has discovered that the main active ingredient in turmeric may have even greater health benefits. News

Suggested Articles

Across its 15-year history, Omega Funds has a hand in a clutch of high-profile biotechs such as Editas Medicine and Juno Therapeutics.

After Novartis’ near $10 billion buyout of The Medicines Company, many thought cardiovascular therapies were hot again.

The data position Leo to file for approval of the Dupixent rival in atopic dermatitis next year.